Gilead/Remdesivir Update: Politics & Methodology Issues Cloud Research

GileadRemdesivir Update Politics & Methodology Issues Cloud Research

As reported by StatNews on May 5, Gilead announced April 29th that remdesivir was found to speed recovery from COVID-19, but effectively changing the study hypotheses midstream leads to doubt about the results. Why, it was asked, did the study’s main goal change only weeks prior? StatNews notes that defining the “primary endpoint” is key. According to some wise people out there, this is analogous to declining to call a shot in pool—you may get credit, but for an accidentally sunk ball. And, “Changing a primary endpoint when you already know the data is even worse. It can even amount to outright research fraud. To mix sports metaphors, researchers often liken it to drawing a target around an arrow after you shot it, and then claiming a bull’s-eye.” 

In defense of the research, the NIAID said “the change was made while still blinded to all outcome data because agency statisticians had performed modeling showing that the original endpoint—an eight-point scale of how subjects were doing that ranged from dead (the worst outcome) to out of the hospital with no restriction on activities and no need for oxygen (the best) on the 15th day of the study—might not detect a difference where ...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee